摘要
目的:探讨系统免疫炎性反应指数(SII)对川崎病(KD)患儿静脉注射免疫球蛋白(IVIG)疗效的预测价值。方法:选取初次确诊并接受IVIG治疗的84例KD患儿作为研究对象,根据对IVIG的疗效分为IVIG敏感组(75例)和IVIG不敏感组(9例),另选取同期仅患呼吸道感染的发热儿童及健康儿童各84例作为对照组。收集各组的血常规结果并计算中性粒细胞淋巴细胞比值(NLR)、血小板淋巴细胞比值(PLR)、SII(中性粒细胞计数×血小板计数/淋巴细胞计数)值,经Logistic回归分析确定IVIG不敏感的危险因素,通过ROC曲线确定NIR、PLR及SII预测KD患儿IVIG不敏感的最佳值。结果:与两组对照组相比,NLR、PLR及SII值均在KD组中偏高,差异有统计学意义(P<0.01);与IVIG敏感组相比,IVIG不敏感组的NLR、PLR及SII值均较高,差异有统计学意义(P<0.05),多因素Logistic回归分析显示NLR、PLR及SII是影响KD患儿IVIG敏感性的独立危险因素,对川崎病IVIG不敏感最佳预测值分别为5.83、206.67和1898.16。结论:SII可作为川崎病IVIG不敏感的预测指标。
Objective To explore the predicting value of systemic immune-inflammation index(SII) as a biomarker in evaluating the intravenous immun globulin(IVIG) resistance of Kawasaki disease(KD).Method 84 children with KD who were first diagnosed and treated with IVIG were selected as the research objects, and divided into IVIG response group(75 cases) and IVIG resistance group(9 cases) according to the efficacy of IVIG. Another 84 children with fever and healthy children who only had respiratory tract infection during the same period were selected as the control group. Routine blood tests of each group were collected and neutrophil lymphocyte ratio(NLR), platelet lymphocyte ratio(PLR) and SII(neutrophil count×platelet count/lymphocyte count) values were calculated. Risk factors for IVIG insensitivity were determined by logistic regression analysis. The optimal cut-off value of SII for predicting IVIG resistance in KD children was determined by ROC curve.Results Compared with the control group, NLR, PLR and SII values were higher in KD group(P<0.01). Compared with the IVIG response group, the values of NLR, PLR and SII in the IVIG resistance group were higher(P<0. 05). Multivariate regression analysis showed that NLR, PLR and SII were independent risk factors for IVIG resistance with KD. The optimal cut-off values for NLR,PLR and SII to predict IVIG resistance of KD are 5.83, 206.67 and 1898.16. Conclusion SII can be used as a predictor of IVIG resistance in KD.
作者
陈梦
尹晓文
CHEN Meng;YIN Xiao-wen(Department of Pediatrics,The First Affiliated Hospital of Shihezi University School of Medicine,Shihezi 832000,China)
出处
《吉林医学》
CAS
2022年第9期2349-2352,共4页
Jilin Medical Journal
